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Abstract
Background: The aim was to compare the occurrence of post-injection dysphagia in parkinsonism-related cervical dystonia (PRCD) versus cervical dystonia (CD)
of other etiologies (non-PRCD). A secondary objective was to explore potential clinical differences between PRCD and non-PRCD and their respective responses to
botulinum toxin (BoNT).
Methods: A cross-sectional chart review was carried out of patients treated for CD with Onabotulinumtoxin A at the University of Florida. We collected
demographic information, dose of BoNT injected, patient-reported presence of dysphagia as a side effect, patient-perceived duration of benefit and efficacy
according to the Clinical Global Impression Scale (CGIS).
Results: Of the 144 patients included, 24 patients were diagnosed with PRCD and 120 were diagnosed as non-PRCD. Data analysis showed no significant
differences in number of weeks of benefit from BoNT (PRCD 9.1¡3.7 versus non-PRCD 9.4¡3.7 weeks, p50.830), BoNT dosage (PRCD 235.0¡95.6 versus
non-PRCD 263.7¡101.3 units, p50.181), median CGIS score (median52 or ‘‘much improved’’ for both groups, p50.88), or the presence of dysphagia after
BoNT (PRCD 17% versus non-PRCD 19 %, p50.753, n5132). In a subgroup analysis of the non-PRCD group, patients who experienced dysphagia were older
than those who did not (63.9¡8.9 years versus 58.1¡14.4 years, p50.02).
Discussion: Despite an increased baseline risk of dysphagia in patients with PRCD, BoNT appears to be equally safe and equally beneficial in PRCD and non-
PRCD patients.
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Introduction
Cervical dystonia (CD) is the most common type of focal dystonia
and consists of sustained muscle contractions leading to abnormal head
posture that may be accompanied by tremor and/or pain.1 CD is
commonly a primary (idiopathic) condition, but can occur secondary
to other disorders such as parkinsonism. Dystonia of any type occurs
in 60% of patients with Parkinson’s disease (PD);2 however, the
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prevalence of CD varies in patients with PD and other types of parkin-
sonism. In general, rates of CD are higher among patients with
atypical parkinsonism than in patients with PD, in which CD is more
likely to develop as the disease progresses. Among all stages of PD,
rates of CD may be as low as 5.8%;3–5 however, among patients in
Hoehn and Yahr stages 4–5, rates of CD have been reported to be
as high as 34%.6,7 In the general PD population, anterocollis is
most common;2 however, in a stage 5 population, 28.4% experience
retrocollis, 4.1% experience anterocollis, and 1.4% experience a
combination of anterocollis and torticollis.7 Despite the relatively high
prevalence of CD in patients with PD and parkinsonism, little
information exists on the safety and efficacy of botulinum toxin
(BoNT) therapy in this patient population. Most of the existing body
of literature on BoNT for CD is based on primary, idiopathic CD.
In primary CD, BoNT injections are an effective and established
treatment (class I evidence, level A recommendations),8 with the advan-
tage of avoiding side effects including sedation, cognitive clouding, and
balance impairment that are commonly associated with oral medica-
tions. Unlike in primary CD, there is no class I evidence that BoNT is
effective in CD associated with PD or parkinsonism. Despite this, it is
widely used in this patient population.2,9
Dysphagia is the most common treatment-related adverse effect of
BoNT therapy, and is believed to occur as a result of regional spread of
the toxin to adjacent pharyngeal muscles,10 particularly after injection
of the sternocleidomastoid (SCM) muscles.2,11 In a large double-blind,
randomized, placebo-controlled clinical trial of Onabotulinum toxin
A, the average rate of dysphagia as an adverse effect of therapy was
19%;12 however, reported rates vary from 1.4% to 27.14%.13–17 PD
patients are vulnerable to the occurrence of dysphagia at baseline. One
meta-analysis found that 35% of PD patients subjectively report
dysphagia, and 82% were found to manifest dysphagia on objective
measures.18 The occurrence of dysphagia in PD increases risk for
aspiration pneumonia 21, so minimizing that risk is critical.
The relationship between BoNT and dysphagia in PD and
parkinsonism patients is not fully understood. Because dysphagia is
already a risk of PD at baseline, we wanted to explore whether PD
patients are more likely to suffer from dysphagia as an acute side effect
of BoNT injections.
The objectives of the present study were to compare the occurrence
of dysphagia post-BoNT injection between PD and parkinsonism-
related CD (PRCD) versus CD of other causes (non-PRCD), and
explore potential differences in clinical characteristics of CD in these
two subgroups.
Methods
This is a retrospective database review from the Institutional Review
Board-approved INFORM database at the University of Florida
Center for Movement Disorders and Neurorestoration. We included
patients who consented to participate in the INFORM database and
were treated with Onabotulinum toxin A injections for CD between
July 2011 and December 2013. Other BoNT preparations were
excluded for consistency of dose comparison. For patients receiving
multiple injections during the study period, only their most recent visit
was analyzed, and for patients initiating their treatments, we excluded
their first two visits as these usually involve gradual titration and dose
finding in our practice. Neurologists trained in movement disorders
administered the BoNT injections and recorded the total units of
BoNT injected per treatment session, potentially including muscles not
directly associated with CD when multiple indications were being
addressed.
For each patient, we gathered demographic information, including
age, gender, and neurologic diagnosis, made by a fellowship-trained
movement disorder neurologist. Other measures included patient-perceived
efficacy acquired via a Clinical Global Impression Scale (CGIS), a 7-point
Likert scale to report CD symptoms as very much improved, much
improved, minimally improved, unchanged, minimally worse, much worse,
or very much worse compared with the baseline. We also acquired the
patient-perceived number of weeks of benefit and the patient-perceived
subjective presence of dysphagia as a side effect of the therapy.
We described categorical variables as counts and percentages, and
analyzed differences in proportions utilizing chi-square testing, with
correction for Fisher’s exact test when appropriate. Ordinal variables were
displayed as medians and we presented continuous variables as means and
standard deviation. We compared means following a normal distribution
with the independent samples t-test and non-parametric variables with the
Mann–Whitney U test. We assumed p#0.05 to be statistically significant
and conducted the statistical analysis with SPSS version 22.0.
Results
Clinical and demographical differences between PRCD and
non-PRCD
Of the 144 patients included in the study, 120 (83%) were diagnosed
with non-PRCD. Within this group, 99 had idiopathic cervical
dystonia, five had post-traumatic dystonia, five had tardive dystonia,
three had psychogenic dystonia, one had DYT1 dystonia, and six had
other secondary cervical dystonias. The remaining 24 (17%) patients
were diagnosed with PRCD. Of these, 20 had PD and four had
atypical parkinsonism. The mean age of the cohort was 60.34¡13.67
years, and 28% of the patients were males. There were no statistically
significant differences between the demographics of the PRCD and
non-PRCD subgroups, with the exception of an even higher
predominance of females in the non-PRCD group (p50.003). Table 1
summarizes the demographic data from both groups.
The reported duration of benefit from the BoNT treatment among
all participants was 9.40¡3.70 weeks. Subgroup analysis demon-
strated no significant difference between duration of clinical benefit
between PRCD (9.25¡3.63 weeks) and non-PRCD (9.43¡3.73
weeks) (p50.830). There was also no difference in the total amount
of BoNT administered between PRCD (233.58¡93.77 units) and non-
PRCD (263.71¡101.34 units) (p50.181). The median self-reported
benefit from the treatment detected by the CGIS was 2 (‘‘much
improved’’ CD symptoms) for both groups. A Mann–Whitney U test
detected no differences between the two groups (p50.879).
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Self-reported symptoms of dysphagia in PRCD and non-PRCD
Self-reported occurrence of dysphagia following BoNT treatment
was available in 132 out of 144 patients. Eighty-one percent (n5107/
132) did not report dysphagia, and 19% (n525/132) reported
dysphagia. Subgroup analysis demonstrated no differences in the
percentage of PRCD (17%) and non-PRCD patients (19%) who repor-
ted symptoms of dysphagia following BoNT treatment (p51.000).
None of the patients with atypical parkinsonism reported dysphagia
following BoNT. Upon performing a post hoc power analysis, the
difference between incidences of 17% reporting dysphagia in the
PRCD group (n524) and 19% in the non-PRCD group (n5108) yield
to a statistical power of 9% for an alpha error of 0.05. Among the
clinical variables, older age had a trend towards statistical significance
when comparing means from the groups reporting dysphagia
(63.24¡8.74 years) and not reporting dysphagia (59.37¡14.24 years),
(p50.09). Additionally, in a subgroup analysis including non-PRCD
patients, the group reporting dysphagia was statistically significantly
older (63.90¡8.90 years) than the group reporting no dysphagia
(58.05¡14.37 years) (p50.022). In a sub-group analysis including
PRCD patients, there was no statistical difference in age between those
reporting dysphagia and those not.
Discussion
In this retrospective study we compared the occurrence of post-
BoNT injection dysphagia in PRCD versus non-PRCD. As a
secondary objective we evaluated for differences in the efficacy of
BoNT among these two groups. The demographics of our study popu-
lation were similar to those reported in the literature when considering
age and gender.14,15 Comparison of the underlying diagnoses of our
patient population to the literature was difficult as most studies either
included only patients with idiopathic cervical dystonia16,19 or inclu-
ded cervical dystonia of any etiology without further delineating
underlying diagnoses.12,15,17 In a study by Jankovic et al.,14 5.8% of
the CD patients also had PD compared with 17% in our sample. We
were unable to compare disease severity as our retrospective database
did not include severity measures.
The peak response to BoNT in our study was similar to what is
reported in the literature.14,19 The duration of response in our patient
population of 9.25¡3.63 weeks in PRCD and 9.43¡3.73 weeks in
non-PRCD was shorter than the 13–16 weeks reported in the
literature.15,17 Our average BoNT doses of 233.58¡93.77 units for
PRCD and 263.71¡101.34 units for non-PRCD were similar to the
mean dose of 236 units reported in the clinical trial on the basis of
which Onabotulinum toxin A received approval for use in CD.12 Our
average doses also fell within the mid-100s to mid-200s range reported
in the literature.13–17,19 Our rates of dysphagia following BoNT of
17% in PRCD and 19% in non-PRCD patients were similar to the
19% reported in the clinical trial on the basis of which Onabotulinum
toxin A received approval for use in CD.12 Our rate of dysphagia also
fell within the range of 1.4–27.14% reported in the literature.13–17
The reported doses of BoNT injected for CD varied widely in the
literature, ranging from 60 to 374 units.13 Most studies reported doses
in the mid-100s to mid-200s range.12,14–17 In our patient population,
Table 1. Clinical and Demographic Characteristics of Study Participants
Non-PRCD (n5120) PRCD (n524) p
Age, years (mean¡SD) 59.6¡13.9 64.0¡12.1 0.125
Gender, n (%)a
Male 27/120 (22.5) 13/24 (54.2) 0.003
Female 93/120 (77.5) 11/24 (45.8)
Diagnosis, n (%)
PD 20/24 (83.3)
Atypical Parkinsonism 4/24 (16.6)
Total Onabotulinum toxin A units (mean¡SD) 263.7¡101.3 233.6¡93.8 0.181
Duration of benefit, weeks (mean¡SD) 9.4¡3.7 9.1¡3.7 0.830
Peak benefit on CGIS (median) 2 2 0.879
Number reporting dysphagia, n (%)1,2 21/108 (19.4) 4/24 (16.7)3 1.000
Abbreviations: CGIS, Clinical Global Impression Scale; PD, Parkinson’s Disease; PRCD, Parkinsonism-related Cervical Dystonia; SD, Standard Deviation.
1Fisher’s exact test performed because of small subgroups.
2Statistics limited to n5108 subjects.
3All PRCD patients who reported dysphagia had PD, not atypical parkinsonism.
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mean doses for each group were on the higher end of the spectrum.
Many factors could contribute to this. In many practices, in order to
avoid common side effects such as dysphagia, patients receive
gradually escalated doses of toxin until the ideal therapeutic effect is
achieved. Some of the studies included patients receiving BoNT for the
first time, but we excluded the first two visits, which may have resulted
in slightly larger doses than other studies. In addition, we did not
exclude patients who received BoNT injections in multiple body
regions at the same injection visit, and the addition of doses from other
body parts to the total BoNT dosage used contributed to higher
average doses in our sample.
The duration of benefit after BoNT in our study was shorter than
the standard 12 week dosing interval that most providers adhere to and
shorter than the 13–16 weeks of efficacy cited in the CD literature.15,17
However, recent studies have shown a considerable number of patients
do experience recurrence of symptoms before 12 weeks, and nearly
half of patients would request another treatment sooner than 12 weeks
if possible.20–22 In addition, disease complexity and severity at our
tertiary referral center as well as inclusion of patients who have been
chronically on therapy may have contributed to higher than average
doses of BoNT and the shorter duration of response; however, severity
data were not collected as part of our retrospective study.
Despite our reported rate of dysphagia being similar to the rate
reported by the large clinical trial that rendered FDA approval for
Onabotulinum toxin A for CD in the United States, some studies
reported markedly lower rates of dysphagia.13,14,16,17 It is possible that
our slightly higher rate of dysphagia is directly related to the higher
doses of BoNT injected, often including co-occurring injections at
other body regions; however, studies correlating BoNT dose with
occurrence of dysphagia are limited. Chapman et al.3 in a large meta-
analysis found no correlation between the two.1 Another possible
explanation relates to our instrument for screening, instructing patients
to ‘‘Please mark any side effects that you may have experienced
following the injection of botulinum toxin.’’ In reviewing these items
with patients after the course of the study, we have realized that
individuals often marked for occurrence of dysphagia that was
unrelated to their injections. Also, there was no distinction between
transient mild increased awareness of need to swallow versus more
significant changes to swallow. Our questionnaire may have encour-
aged over-reporting, resulting in more positive responses. At the same
time, it is critical to note that relying on self-reporting of dysphagia has
been shown traditionally to under-report, and future studies could
more accurately assess safety by incorporating objective measures.
We did not identify any difference in the rate of dysphagia among
our non-PRCD and PRCD groups, rejecting our hypothesis, which to
our current knowledge, has not been previously identified in the
literature. A possible explanation is that, similarly to patients with PD
and parkinsonism who have baseline dysphagia 20–30% of the time,23
CD patients also experience baseline dysphagia 22.7% of the time,
independently of BoNT treatment.16 Another reason for similar rates
of dysphagia may be that we frequently incorporate injections of the
SCM muscles in both groups: for anterocollis in the PRCD group and
for torticollis in the non-PRCD group. According to the literature,
total BoNT dosage injected in the SCM muscles correlates with the
occurrence of dysphagia as an adverse effect of BoNT. Borodic et al.10
showed a direct correlation between BoNT dosing injected in SCM
and occurrence of dysphagia, where patients receiving a median dose
of 150 units developed dysphagia, whereas patients receiving a median
SCM injection of 100 units did not develop dysphagia. Our study was
a pilot to look at overall safety, but our database did not capture the
pattern of dystonia, muscles injected, and dose per muscle. Examining
these data in the future would provide greater depth of understanding
of risks.
The strengths of this study are that it addresses an important gap in
knowledge about safety and efficacy of BoNT for CD related to PD
and parkinsonism. Our results suggest that patients with CD related
to parkinsonism can be treated just as safely as those with CD of
other etiologies. In addition, the study design allowed for inclusion of
patients of CD of any etiology, not just idiopathic CD. This more
closely mimics the patient mix cared for in a typical tertiary referral
center for dystonia. A few potential limitations of this study exist. The
first is that a relatively small and heterogeneous subgroup of PRCD
patients (n524) was enrolled in this retrospective study, prompting the
need for larger studies to replicate, confirm, and generalize our
findings to the broader population of parkinsonian patients. Some of
our null findings could have been influenced by low power associated
with small sample sizes. Considering the same proportions as repre-
sentatives of the total population of these subgroups in order to identify
a statistically significant difference between the two proportions at a
power level of 80%, a redesigned study would require thousands of
patients in each group. This large sample size would be difficult to
achieve outside of a multicenter study. A second limitation is that
many of the data were based on patient reporting instead of objective
measures. No objective method of quantifying the initial severity
of CD prior to BoNT was incorporated. The pre-BoNT presence of
dysphagia was not assessed and the duration and severity of post-
BoNT dysphagia were not assessed with radiographic studies or a
formal swallow evaluation. In addition, we did not assess comorbidities
that may act as confounders and influence dysphagia risk. Finally, our
calculation of total dose of BoNT included all body parts instead of
cervical muscles only, and our database does not contain information
regarding individual doses for each specific muscle. Therefore, we
could not establish correlations between dysphagia and muscle-specific
BoNT doses. Additionally, patients who received BoNT injections in
other body parts may have inflated the average dose in our results, and
despite reflecting ‘‘real-world’’ treatment patterns, this precludes direct
comparison with other studies. Though BoNT in PRCD appears to be
well tolerated on the basis of self-report, a prospective study involving a
larger sample of PRCD patients using objective measures of pre- and
post-BoNT dysphagia should be performed to confirm or reject our
findings.
In conclusion, this study suggests that patients receiving BoNT
injections for PRCD had a similar reported degree and duration of
benefit and did not differ in the self-reported occurrence of dysphagia
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when compared with patients receiving BoNT for CD of other
etiologies. Of the clinical and demographic variables, age seems to
correlate with the occurrence of dysphagia, independently of diagnosis;
however, the duration of benefit and total BoNT dose administered
did not. These results suggest that BoNT is equally safe and effective
for patients with PRCD and patients with CD of other causes, based
on our retrospective pilot study. Larger studies with attention to
cervical dystonia subtypes, specific muscles injected and doses may
help further elucidate optimal injection practices.
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